A Study of YM178 in Patients With Symptomatic Overactive Bladder

Astellas Pharma Inc842 enrolled

Overview

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo

To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

842

Conditions

Urinary Bladder, Overactive

Interventions

YM178DRUG

Oral

PlaceboDRUG

Oral

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 20 years suffering from overactive bladder Exclusion Criteria: * Pregnant and breastfeeding women * Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study

Locations (5)

Unnamed facility

Chūbu, Japan

Unnamed facility

Hokkaido, Japan

Unnamed facility

Kansai, Japan

Unnamed facility

Kanto, Japan

Unnamed facility

Kyusyu, Japan

Outcomes

Primary Outcomes

Overactive bladder symptoms

Time frame: 12 weeks

Secondary Outcomes

Overactive bladder symptoms (QOL)

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.